Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm

NEW YORK, Jan. 8, 2024

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

• Karuna Therapeutics, Inc. (Nasdaq: KRTX)

Bristol Myers Squibb has agreed to acquire Karuna in a transaction valued at an estimated $14 billion. Under the agreement, shareholders of Karuna Therapeutics will be entitled to a payment of $330.00 per share in cash.

• Daseke, Inc. (Nasdaq: DSKE)

Daseke has agreed to be acquired by TFI International in a cash deal worth about $1.1 billion.  Under the proposed transaction, Daseke shareholders will receive $8.30 per share in cash.

• RayzeBio, Inc. (Nasdaq: RYZB)

Bristol Myers Squibb has agreed to purchase RayzeBio in an all-cash deal valued at around $4.1 billion. In accordance with the merger agreement, RayzeBio shareholders are set to receive $62.50 per share in cash.

• Gracell Biotechnologies Inc. (Nasdaq: GRCL)

Under the proposed transaction AstraZeneca will purchase Gracell for $2.00 per ordinary share in cash, equivalent to $10.00 per Gracell ADS. A contingent value right of $0.30 per ordinary share (or $1.50 per Gracell ADS) in cash will be paid upon reaching a specific regulatory milestone.